European and Developing Countries Clinical Trials Partnership (EDCTP3)

Instititutionalised

https://research-and-innovation.ec.europa.eu/research-area/health/edctp_en

https://research-and-innovation.ec.europa.eu/system/files/2023-04/edctp_work_programme_2023.pdf

https://commission.europa.eu/system/files/2022-01/ec_rtd_edctp3-sria-2022.pdf

Infectious diseases; sub-Saharan Africa.

The total budget of the GH EDCTP3 JU will be of up to €1.6 billion. The EU’s financial contribution to the GH EDCTP3 Joint Undertaking will be €800 million. The EDCTP Association will contribute at least €400 million, and another €400 million is expected from other contributing partners, such as philanthropic organisations and industry.

Swiss entities can participate in the EDCTP3 Partnership’s calls as Associated Partners from a non-associated third country. Swiss Associated Partners do not count towards the minimum/maximum number of participants. 

Swiss entities are not eligible for receiving EDCTP3 funding. However, Swiss entities can request funding from the Swiss State Secretariat for Education, Research, and Innovation (SERI) if the project proposal they are part of is successfully selected. 

No. Associated Partners cannot act as project coordinators. However, they can be Work Package Leaders. 

EDCTP3 has introduced the concept of “Scientific Project Leader” within each consortium to ensure that all partners in the funded consortia have equal opportunities to lead the scientific work of the project. Swiss entities cannot be Scientific Project Leaders.

Further information on eligibility, requirements, and funding rates covered for Swiss entities participating as associated partners can be found in our Legal & Finance page.

Calls for proposals can be found here and in the Funding & Tenders Portal.